These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 37994574)
21. Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1. Du W; Machalz D; Yan Q; Sorensen EJ; Wolber G; Bureik M Biochem Pharmacol; 2020 Apr; 174():113850. PubMed ID: 32044355 [TBL] [Abstract][Full Text] [Related]
22. Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues. Al-Saraireh YM; Alboaisa NS; Alrawashdeh HM; Hamdan O; Al-Sarayreh S; Al-Shuneigat JM; Nofal MN Ecancermedicalscience; 2020; 14():1114. PubMed ID: 33144882 [TBL] [Abstract][Full Text] [Related]
24. Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers. Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Tarawneh F; Al-Sarayreh S; Almuhaisen GH; Satari AO; Al-Shuneigat J; Alrawashdeh HM Breast Cancer (Dove Med Press); 2021; 13():565-574. PubMed ID: 34675653 [TBL] [Abstract][Full Text] [Related]
25. Conditional regulation of the human CYP4X1 and CYP4Z1 genes. Savas U; Hsu MH; Griffin KJ; Bell DR; Johnson EF Arch Biochem Biophys; 2005 Apr; 436(2):377-85. PubMed ID: 15797250 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, metabolism and off-target effects in the rat of 8-[(1H- benzotriazol-1-yl)amino]octanoic acid, a selective inhibitor of human cytochrome P450 4Z1: Kowalski JP; Pelletier RD; McDonald MG; Kelly EJ; Rettie AE Xenobiotica; 2021 Aug; 51(8):901-915. PubMed ID: 33993844 [TBL] [Abstract][Full Text] [Related]
27. Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer. Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M Immunobiology; 2022 Mar; 227(2):152174. PubMed ID: 34999392 [TBL] [Abstract][Full Text] [Related]
28. The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells. Leung HW; Ko CH; Yue GG; Herr I; Lau CB Cancer Chemother Pharmacol; 2018 Aug; 82(2):185-197. PubMed ID: 29777274 [TBL] [Abstract][Full Text] [Related]
29. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Zöllner A; Dragan CA; Pistorius D; Müller R; Bode HB; Peters FT; Maurer HH; Bureik M Biol Chem; 2009 Apr; 390(4):313-7. PubMed ID: 19090726 [TBL] [Abstract][Full Text] [Related]
30. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer. Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583 [TBL] [Abstract][Full Text] [Related]
31. Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Sarayreh S; Almuhaisen GH; Alnawaiseh N; Al Shuneigat JM; Alrawashdeh HM Sci Rep; 2021 Mar; 11(1):5581. PubMed ID: 33692504 [TBL] [Abstract][Full Text] [Related]
32. Profiling the expression of cytochrome P450 in breast cancer. Murray GI; Patimalla S; Stewart KN; Miller ID; Heys SD Histopathology; 2010 Aug; 57(2):202-11. PubMed ID: 20716162 [TBL] [Abstract][Full Text] [Related]
33. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation. Al-Dhfyan A; Alhoshani A; Korashy HM Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884 [TBL] [Abstract][Full Text] [Related]
34. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Downie D; McFadyen MC; Rooney PH; Cruickshank ME; Parkin DE; Miller ID; Telfer C; Melvin WT; Murray GI Clin Cancer Res; 2005 Oct; 11(20):7369-75. PubMed ID: 16243809 [TBL] [Abstract][Full Text] [Related]
35. Concomitant occurence of multiple autoantibodies against human cytochromes P450. Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M Int Immunopharmacol; 2021 Nov; 100():108087. PubMed ID: 34464888 [TBL] [Abstract][Full Text] [Related]
36. Transmembrane protein TMEM119 facilitates the stemness of breast cancer cells by activating Wnt/β-catenin pathway. Yang B; Wang F; Zheng G Bioengineered; 2021 Dec; 12(1):4856-4867. PubMed ID: 34334123 [TBL] [Abstract][Full Text] [Related]
37. Anillin regulates breast cancer cell migration, growth, and metastasis by non-canonical mechanisms involving control of cell stemness and differentiation. Wang D; Naydenov NG; Dozmorov MG; Koblinski JE; Ivanov AI Breast Cancer Res; 2020 Jan; 22(1):3. PubMed ID: 31910867 [TBL] [Abstract][Full Text] [Related]
38. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042 [TBL] [Abstract][Full Text] [Related]
39. Anti-CYP4Z1 autoantibodies detected in breast cancer patients. Nunna V; Jalal N; Bureik M Cell Mol Immunol; 2017 Jun; 14(6):572-574. PubMed ID: 28435160 [No Abstract] [Full Text] [Related]
40. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]